# Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

> **NCT02071862** · PHASE1 · COMPLETED · sponsor: **Calithera Biosciences, Inc** · enrollment: 210 (actual)

## Conditions studied

- Solid Tumors
- Triple-Negative Breast Cancer
- Non Small Cell Lung Cancer
- Renal Cell Carcinoma
- Mesothelioma
- Fumarate Hydratase (FH)-Deficient Tumors
- Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)
- Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors
- Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations
- Tumors Harboring Amplifications in the cMyc Gene

## Interventions

- **DRUG:** CB-839
- **DRUG:** Pac-CB
- **DRUG:** CBE
- **DRUG:** CB-Erl
- **DRUG:** CBD
- **DRUG:** CB-Cabo

## Key facts

- **NCT ID:** NCT02071862
- **Lead sponsor:** Calithera Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02071862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02071862, "Study of the Glutaminase Inhibitor CB-839 in Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02071862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*